Analyst Consensus ?
ConsensusBuy20 ratings
Bullish1365.0%
Neutral735.0%
Bearish00.0%
Nordson Corporation · NDSN · FY2026 Q2 · Calendar Q2 2026
Nordson Q2 FY2026: Record Sales, EBITDA, and Raised Guidance on Broad-Based Growth
Nordson delivered its second consecutive quarter of record results, with Q2 FY2026 sales of $741 million (up 8% YoY, 7% organic) and record EBITDA of $235 million at a 32% margin. All three segments contributed to organic growth. The company raised full-year guidance for the second straight quarter, now pointing to $2.93–$3.01 billion in sales and $11.30–$11.80 in adjusted EPS. Backlog grew 18% organically, providing visibility into second-half demand. The CapstanAG acquisition expands precision agriculture, while a zero-cash pension annuitization de-risks the balance sheet. Management tone remained confident, though inflationary costs, tariff pressures, and a regulatory-driven medical product change pose near-term margin headwinds.
Reported After market closeNASDAQIndustrials
$16.45B market cap
100quality score
Company context
Snapshot as of publicationNordson Corporation engineers, manufactures, and markets products and systems to dispense, apply, and control adhesives, coatings, polymers, sealants, biomaterials, medical components, and other fluids. The Industrial Precision Solutions segment provides dispensing, coating, and laminating systems for adhesives, lotions, liquids, and fibers to disposable products and roll goods; automated adhesive dispensing systems; components and systems for thermoplastic and biopolymer melt stream; fluid components, such as nozzles, pumps, and filters; smart components that measure and control the flow, quantity and location of dispensed fluid; control systems; and product assembly solutions. It also offers automated and manual dispensing products and systems for cold materials, container coating, liquid finishing, and powder coating, as well as ultraviolet equipment.…
Earnings scorecard
Reported versus consensus
Reported EPS
$2.86
Consensus $3
EPS surprise
+1.4%
Reported versus consensus
Reported revenue
$740.8M
Consensus $728.8M
Revenue surprise
+1.7%
Reported versus consensus
Earnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$295.23Previous close
$240Low
$290.79Average
$345High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Jul 31, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Oppenheimer | Outperform | Outperform | Maintain | May 29, 2026 |
| DA Davidson | Buy | Buy | Maintain | May 27, 2026 |
| BNP Paribas | Neutral | Neutral | Maintain | May 22, 2026 |
| Baird | Neutral | Neutral | Maintain | Feb 20, 2026 |
| Keybanc | Overweight | Overweight | Maintain | Feb 19, 2026 |
| Loop Capital | Buy | Hold | Upgrade | Jan 22, 2025 |
| Seaport Global | Buy | Neutral | Upgrade | Dec 17, 2024 |
| Wells Fargo | Overweight | Overweight | Maintain | Feb 23, 2024 |
| Jefferies | Hold | Buy | Downgrade | Sep 26, 2023 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jun 9, 2022 |
| B. Riley Securities | Buy | Buy | Maintain | May 23, 2018 |
| B. Riley FBR | Buy | Buy | Maintain | May 23, 2018 |
| Gabelli & Co. | Hold | Buy | Downgrade | Dec 15, 2017 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | Aug 23, 2016 |
| Wunderlich Securities | Buy | Hold | Upgrade | Jan 7, 2016 |
| Wunderlich | Buy | Hold | Upgrade | Jan 7, 2016 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Dec 14, 2015 |
| BB&T Capital | Buy | Hold | Upgrade | Oct 10, 2014 |
| Barrington Research | Outperform | Market Perform | Upgrade | Jun 18, 2014 |
| BMO Capital | Market Perform | Outperform | Downgrade | May 24, 2013 |
Named analyst price targets
Upside is calculated against the persisted previous close $295.23. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Oppenheimer | Analyst unavailable | $335 | $287.66 | +13.5% | May 29, 2026 |
| D.A. Davidson | Analyst unavailable | $345 | $287.91 | +16.9% | May 27, 2026 |
| Oppenheimer | Analyst unavailable | $325 | $292.66 | +10.1% | Feb 24, 2026 |
| Jefferies | Saree Boroditsky | $300 | $289.98 | +1.6% | Feb 23, 2026 |
| D.A. Davidson | Analyst unavailable | $335 | $290.13 | +13.5% | Feb 23, 2026 |
| Robert W. Baird | Analyst unavailable | $314 | $293.93 | +6.4% | Feb 20, 2026 |
| KeyBanc | Analyst unavailable | $325 | $299.29 | +10.1% | Feb 19, 2026 |
| Vertical Research | Analyst unavailable | $270 | $237.37 | -8.5% | Dec 15, 2025 |
| D.A. Davidson | Analyst unavailable | $290 | $235.21 | -1.8% | Dec 12, 2025 |
| Robert W. Baird | Analyst unavailable | $275 | $234.45 | -6.9% | Dec 12, 2025 |
| KeyBanc | Jeffrey Hammond | $295 | $236.19 | -0.1% | Dec 11, 2025 |
| D.A. Davidson | Matthew Summerville | $285 | $239.06 | -3.5% | Oct 21, 2025 |
| Oppenheimer | Analyst unavailable | $275 | $225.79 | -6.9% | Aug 25, 2025 |
| Robert W. Baird | Analyst unavailable | $252 | $227.17 | -14.6% | Aug 22, 2025 |
| Jefferies | Analyst unavailable | $240 | $219.93 | -18.7% | Aug 21, 2025 |
| KeyBanc | Analyst unavailable | $260 | $206.55 | -11.9% | Mar 4, 2025 |
| Robert W. Baird | Michael Halloran | $287 | $256.03 | -2.8% | Aug 23, 2024 |
| Loop Capital Markets | Chris Dankert | $255 | $246.44 | -13.6% | May 22, 2024 |
| Robert W. Baird | Michael Halloran | $272 | $245.85 | -7.9% | May 22, 2024 |
| D.A. Davidson | Matthew Summerville | $295 | $243.14 | -0.1% | May 21, 2024 |
| D.A. Davidson | Matt Summerville | $270 | $232.33 | -8.5% | Aug 21, 2023 |
| KeyBanc | Jeffrey Hammond | $255 | $221.04 | -13.6% | Feb 22, 2023 |
| Robert W. Baird | Analyst unavailable | $271 | $239.17 | -8.2% | Aug 24, 2022 |
| Morgan Stanley | Analyst unavailable | $250 | $218.04 | -15.3% | Jun 9, 2022 |
| Berenberg Bank | Andrew Buscaglia | $300 | $222.06 | +1.6% | Jun 7, 2022 |
Track every rating change on NDSN the moment it posts. Free to start.
Start freeMarket reaction
event-close to next-session close
Stock move
+3.8%
Event window
SPY move
+0.2%
Same window
Abnormal move
+3.6%
Stock minus SPY
Volume
2.2×
Versus trailing sessions
Subsequent drift
+2.9%
Up to 20 sessions
NDSNSPY benchmark
Follow NDSN with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
Nordson raised full-year FY2026 guidance for the second consecutive quarter, widening the sales range to $2.93–$3.01 billion (from $2.86–$2.98 billion) and lifting adjusted EPS to $11.30–$11.80 (from $11.00–$11.60). Q2 sales of $741 million topped the prior quarter's $669 million, with EBITDA margin expanding to a record 32%. Backlog grew 18% organically. The company completed the CapstanAG acquisition (precision agriculture, ~$13M revenue, 9x EBITDA) and annuitized $113 million of U.S. pension obligations.
Guidance delta
Full-year FY2026 sales guidance raised to $2.93–$3.01 billion from $2.86–$2.98 billion. Adjusted EPS guidance raised to $11.30–$11.80 from $11.00–$11.60. Both represent the second consecutive guidance increase, reflecting continued semiconductor demand, broad-based organic growth, and the CapstanAG acquisition.
Key takeaways
- Q2 sales of $741 million, up 8% YoY with 7% organic growth across all three segments.
- Record EBITDA of $235 million at a 32% margin, demonstrating strong operating leverage.
- Full-year guidance raised to $2.93–$3.01 billion in sales and $11.30–$11.80 in adjusted EPS.
- Backlog grew 18% organically, supporting confidence in second-half demand.
- CapstanAG acquisition expands precision agriculture; $113M pension annuitization de-risks the balance sheet.
- Free cash flow conversion above 100% for the fourth consecutive quarter (119%).
Management priorities
- Deploy cash through dividends, share repurchases, and debt reduction.
- Pursue additional bolt-on acquisitions, particularly in medical and precision technology.
- Invest $10 million in capex projects to support organic growth.
- Integrate CapstanAG facilities in Topeka to serve mid-tier OEM customers.
- Advance test and inspection capabilities within the ATS segment.
Related earnings events
IndustrialsROL · FY2026 Q2 · Calendar Q3 2026Rollins Q2 2026: Revenue Misses as Digital Lead Slowdown Hits OrkinLUV · FY2026 Q2 · Calendar Q3 2026Southwest Airlines Q2 2026: EPS Beats by 84%, Unit Revenue Up 20%, Guidance Cut on FuelDOV · FY2026 Q2 · Calendar Q3 2026Dover Raises EPS Guidance but Shares Fall 8% on Revenue Miss and Refrigeration Issues
Sources
- Earnings call transcript and parsed analysis · 2026-05-21T18:22:17.212369+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-07-31T07:51:23.175748+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-31T07:51:23.172963+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.